# of Displayed Technologies: 20 / 21

Applied Category Filter (Click To Remove): Therapeutics


Categories

An improved base editor (iABE-NG) for correcting genetic diseases such as Duchenne muscular dystrophy
TS-049505 — An engineered base editor (iABE-NG) that uses an SpCas9 variant, a shortened adenine deaminase domain with eliminated RNA off-targeting activity, and an intein split for packaging into an adeno-associated virus (AAV), resulting in gene mutation correction.
There are thousands of monogenic diseases such as Duchenne muscular dystrophy (DMD) lacking effective therapeutic treatments. DMD is caused by genetic mutations in the DMD gene, which encodes the dystrophin protein. The mutations including missense point mutations, nonsense point mutations, deleti…
  • College: College of Medicine (COM)
  • Inventors: Han, Renzhi; Gao, Yandi; Xu, Li
  • Licensing Officer: Davis, Stewart

Live vaccine candidate for Chagas disease
TS-044084 — Trypanosoma cruzi is a protozoan parasite that causes Chagas disease, a PRV-eligible disease that is the leading cause of heart failure in Latin America. Due to migration of infected hosts from endemic regions, Chagas disease is also a growing public health concern in the USA and other migrant des…
  • College: College of Medicine (COM)
  • Inventors: McGwire, Bradford
  • Licensing Officer: Ezzell, Janel

Live vaccine candidate for Chagas disease
TS-044084 — Trypanosoma cruzi is a protozoan parasite that causes Chagas disease, a PRV-eligible disease that is the leading cause of heart failure in Latin America. Due to migration of infected hosts from endemic regions, Chagas disease is also a growing public health concern in the USA and other migrant des…
  • College: College of Medicine (COM)
  • Inventors: McGwire, Bradford
  • Licensing Officer: Ezzell, Janel

Translational Activators of the Glutamate Transporter EAAT2 to Treat Neurological and Psychiatric Diseases
TS-043938 — Small molecule technology with novel translational activation mechanism.
Glutamate is a major neurotransmitter in the mammalian central nervous system (CNS) and essential for normal brain function including cognition, memory, and learning. However, the extracellular concentration of glutamate must remain below excitotoxic levels (~ 1 μM) to avoid overstimulation of
  • College: College of Medicine (COM)
  • Inventors: Lin, Chien-Liang; Hodgetts, Kevin
  • Licensing Officer: Dahlman, Jason "Jay"

Treatment of Multiple Sclerosis with Small Molecule IL-6/STAT3 Inhibitors
TS-038701 — Small-molecule prodrugs that target IL-6/STAT3 signaling pathway.
Multiple Sclerosis (MS), an unpredictable and disabling autoimmune disease affecting the central nervous system, is the leading cause of non-traumatic neurological disability in young adults. There have been important advances in MS therapy, such as drugs that slow the progression of the disease a…
  • College: College of Medicine (COM)
  • Inventors: Yang, Yuhong; Li, Chenglong; Racke, Michael
  • Licensing Officer: Ezzell, Janel

Methods for generation of TF-targeting chimeric antigen receptors (CARs)-natural killer cells and T cells
TS-038262 — A therapeutic application of neovascular-targeting chimeric antigen receptor (CAR) T cells and NK cells for treating diseases associated with pathological angiogenesis, in which TF is abarrently expressed, such as solid tumors, leukemia, lymphoma, age-related macular degeneration (AMD), endometriosis, and rheumatoid arthritis.
Nearly 2,000,000 new cancer cases are expected to be diagnosed each year in the United States. Available treatment options include surgery, radiation therapy, chemotherapy, and immunotherapy. Recently, cell-based immunotherapy utilizing specific chimeric antigen receptor (CAR) expressing immune ce…
  • College: College of Medicine (COM)
  • Inventors: Hu, Zhiwei
  • Licensing Officer: Ezzell, Janel

A novel STK1-targeted small molecule as an "antibiotic resistance breaker"
TS-037880 — Inh2-B1 serves as a therapeutically important “antibiotic-resistance-breaker,” which enhances the bactericidal activity of Ceftriaxone/Cefotaxime against highly pathogenic MDRSA infection.
Highly pathogenic and multidrug-resistant Staphylococcus species encompasses methicillin-resistant strains of S. aureus (MDRSA) and S. epidermidis (MDRSE) that have developed resistance to multiple traditional antibiotics, including the 5th generation cephalosporin (Ceftaroline). Because of the re…
  • College: College of Medicine (COM)
  • Inventors: Pancholi, Vijay
  • Licensing Officer: Davis, Stewart

A novel STK1-targeted small molecule as an "antibiotic resistance breaker"
TS-037880 — Inh2-B1 serves as a therapeutically important “antibiotic-resistance-breaker,” which enhances the bactericidal activity of Ceftriaxone/Cefotaxime against highly pathogenic MDRSA infection.
Highly pathogenic and multidrug-resistant Staphylococcus species encompasses methicillin-resistant strains of S. aureus (MDRSA) and S. epidermidis (MDRSE) that have developed resistance to multiple traditional antibiotics, including the 5th generation cephalosporin (Ceftaroline). Because of the re…
  • College: College of Medicine (COM)
  • Inventors: Pancholi, Vijay
  • Licensing Officer: Davis, Stewart

Use of Gene Product to Treat Nerve Injury and Sarcopenia
TS-037778 — A novel method using the overexpression of survival motor neuron protein to improve motor unity synaptic repair and restore/protect muscle size and function due to sarcopenia
Sarcopenia, the age-related wasting and loss of strength, is an important neuromuscular problem of aging. It affects up to 50% of individuals by the 8th decade, and can lead to impaired mobility, loss of independence, and increased risk of mortality. The neuromuscular system is comprised of groups…
  • College: College of Medicine (COM)
  • Inventors: Burghes, Arthur; Arnold, William; Kaspar, Brian; McGovern, Vicki
  • Licensing Officer: Ezzell, Janel

Antisense Oligonucleotide Development for Treatment of Spinal Muscular Atrophy
TS-037741 — The SMN2 gene contains sequences that regulate the level of inclusion of SMN exon7 in SMN mRNA, and some of these act in a negative manner. Antisense oligonucleotides to block the negative regulating protein binding to these sites can increase inclusion of SMN exon 7 and thus, the amount of SMN being produced.
Spinal muscular atrophy (SMA) is a genetic disorder that affects the control of muscle movement. It is caused by a loss of motor neurons in the spinal cord and brainstem, leading to weakness and atrophy in the muscles used for walking, crawling, sitting up, and head movement. In severe instances, …
  • College: College of Medicine (COM)
  • Inventors: Burghes, Arthur; McGovern, Vicki; Prior, Thomas
  • Licensing Officer: Ezzell, Janel

Cbl-b Inhibition as a Therapeutic Approach to Disseminated Candidiasis
TS-037695 — Disseminated C. albicans infection in patients who have a weakened immune system is life threatening and causes 40% of bloodstream infections (candidemia) in hospitals. Despite the availability of several anti­fungal drugs, invasive candidiasis still has a high mortality rate ranging from 19-4…
  • College: College of Medicine (COM)
  • Inventors: Zhang, Jian; Rappleye, Chad
  • Licensing Officer: Davis, Stewart

Discovery of a novel CD34(+) natural killer precursor population in human lymph nodes
TS-037651 — Ohio State University researchers have discovered novel subset of human CD34 (+) hematopoietic precursor cells and generated a method of isolating them.
Natural killer (NK) cells are a type of lymphocyte that plays a role in the immune system. These cells can react against and destroy another cell without prior sensitization to it. The role of NK cells in tumor activity is known, but recent research has also linked them to other immune disease con…
  • College: College of Medicine (COM)
  • Inventors: Caligiuri, Michael; Becknell, Michael; Freud, Aharon
  • Licensing Officer: Paschall, Christopher

Antisense Morpholino Treatment to Increase SMN Levels and Treat Spinal Muscular Atrophy
TS-037648 — A treatment for spinal muscular atrophy.
Spinal Muscular Atrophy (SMA) is caused by deletion or mutation of SMN1 and retention of SMN2, this in turn leads to reduced levels of the full SMN protein. SMA is the second leading cause of neuromuscular disease, and many people living with SMA need round-the-clock care from their families and a…
  • College: College of Medicine (COM)
  • Inventors: Burghes, Arthur; Porensky, Paul
  • Licensing Officer: Ezzell, Janel

Autophagosome-Lysosome Fusion Inhibition Enhances Flavopiridol Efficacy in Cancer
TS-037639 — A novel method to increase the effectiveness and practicality of the cancer treatment drug Flavopiridol.
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia and the current therapies are not curative. High-risk genetic modifications are associated with poor response to traditional therapies. Flavopiridol, a broad-spectrum cyclin-dependent kinase inhibitor, activates significant clini…
  • College: College of Medicine (COM)
  • Inventors: Byrd, John; Grever, Michael; Johnson, Amy; Lucas, David; Mahoney, Emilia
  • Licensing Officer: Ezzell, Janel

Combination Agent Approach for Improved Expansion and Mobilization of Hematopoietic Stem Cells
TS-037629 — Combined treatment of plerixafor and Flt3L better mobilize stem cells and do not exacerbate graft-versus-host disease following transplatation.
Hematopoietic stem cell transplantation (HSCT) is used in patients with hematologic malignancies resulting from irradiation and graft-versus-tumor effects. However, patients who undergone HSCT may suffer complications such as graft-versus-host disease (GVHD), infection, and relapse. The most commo…
  • College: College of Medicine (COM)
  • Inventors: Yu, Jianhua; Caligiuri, Michael; Devine, Steven
  • Licensing Officer: Paschall, Christopher

Targeting EGFL7 in AML
TS-037353 — Treatment of blood cancer with anti-EGFL7 antibody.
Despite recent progress in understanding acute myeloid leukemia (AML) biology and the use of intensive treatments, the long-term overall survival is only 30-40% in younger (<60 years) and <10% in older adult AML patients. This highlights the urgent need for novel therapeutic approaches for a…
  • College: College of Medicine (COM)
  • Inventors: Dorrance, Adrienne; Garzon, Ramiro; Shen, Changxian
  • Licensing Officer: Ezzell, Janel

Gene delivery to adipose tissue using novel recombinant adeno-associated viral (AAV) vectors
TS-037310 — An engineered recombinant adeno-associated virus capable of targeting visceral fat tissue for the purposes of genetic manipulation.
Recombinant adeno-associated viruses (rAAVs) are effective tools for delivering gene therapy treatment and for manipulation of acquired diseases. However, there is no effective method to target adipose tissue and transduction efficiency is low in naturally occurring AAV serotypes. In addition, cur…
  • College: College of Medicine (COM)
  • Inventors: Cao, Lei; Huang, Wei
  • Licensing Officer: Ezzell, Janel

Oncolytic Virus Expressing Angiostatic Factors under an Immediate Early Viral Promoter
TS-015264 — Tumor-targeting oncolytic virus is able to kill cancer cells while sparing normal cells and encodes anti-angiogenic factors that reduced blood vessel formation and may modulate innate immune response.
Glioblastoma is the most common primary malignant brain tumor, with a median survival of less than 15 months from diagnosis. Current standard of care combines surgical resection, with radiation and chemotherapy. However, many patients recur with resistant tumors that require alternative treatments…
  • College: College of Medicine (COM)
  • Inventors: Kaur, Balveen; Chiocca, Ennio; Saeki, Yoshinaga
  • Licensing Officer: Davis, Stewart

Therapuetic Agent for B Cell Malignancies
TS-015099 — A small molecule that functions as an agonist of the sphingosine receptor mediated signaling and interferes with lymphocyte trafficking.
In 2020, there will be an estimated 200,000 new cases of blood cancer in the United States. Blood cancer such as chronic lymphocytic leukemia (CLL), Non-Hodgkin's Lymphoma (NHL), and acute lymphoblastic leukemia (ALL) are typically treated with a combination of chemotherapy, radiation, and bio…
  • College: College of Medicine (COM)
  • Inventors: Byrd, John; Chen, Ching-Shih; Muthusamy, Natarajan; Perrotti, Danilo
  • Licensing Officer: Ezzell, Janel

miR-3151 and BAALC as a Target for Drug Therapy
TS-014895 — Identified gene target for treatment of human acute leukemia, brain tumors and melanoma
Treatment failure is one of the leading causes of death in patients with human acute leukemia, yet the cause of treatment failure is still largely unknown. Overexpression of the RNA gene miR-3151 and its host gene, Brain and Acute Leukemia, Cytplasmic (BAALC), is a sign of an ineffective treatment…
  • College: College of Medicine (COM)
  • Inventors: de la Chapelle, Albert; Eisfeld, Ann-Kathrin; Tanner, Stephan
  • Licensing Officer: Dahlman, Jason "Jay"

Show More Technologies

Loading icon